

2 September 2024

Neurofibromatosis type 1

I would like to inquire about access to information on type 1 Neurofibromatosis. I would like to submit an FOI request to the Belfast Health and Social Care Trust for the following information below - Time Frame: July 2023 - June 2024

1. The number of patients with Neurofibromatosis Type 1 who got treated

Between July 2023 and June 2024, there were <5 patients treated in Belfast Trust with Neurofibromatosis Type 1.

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. The volume of medication dispensed and/or consumed

List of medication:

- **Selumetinib** As per question 1, the Trust is unable to respond as there were <5 patients treated and to provide this information could make patients personally identifiable.
- **Binimetinib** This medicine has other indications and it is not possible to link the data for drug with indication.
- **Cabozantinib** This medicine has other indications and it is not possible to link the data for drug with indication.
- **Trametinib** This medicine has other indications and it is not possible to link the data for drug with indication.